EDG-7500 is a small molecule commercialized by Edgewise Therapeutics, with a leading Phase II program in Hypertrophic Cardiomyopathy. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of EDG-7500’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for EDG-7500 is expected to reach an annual total of $119 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
EDG-7500 Overview
It was also under development for the treatment of adult neuromuscular disorders, metabolic disorders and heart failure with preserved ejection fraction.
Edgewise Therapeutics Overview
Edgewise Therapeutics is a pharmaceutical company that discovers, develops and commercializes of innovative products to treat severe and rare muscle disorders. The company’s product portfolio includes EDG-5506, EDG-5440 and EDG-002. Its products are used in various therapeutic areas such as duchenne, limb-girdle and becker muscular dystrophy, hypertrophic cardiomyopathy, McArdle disease (also known as Glycogen storage disease type V or GSDV) and rare neuromuscular disease. Edgewise Therapeutics collaborates with a network of experts who advise and support its development activities. The company utilizes translatable systems to identify small-molecule precision medicines which regulate key proteins in muscle tissue. Edgewise Therapeutics is headquartered in Boulder, Colorado, the US.
The operating loss of the company was US$114.4 million in FY2023, compared to an operating loss of US$71.7 million in FY2022. The net loss of the company was US$100.2 million in FY2023, compared to a net loss of US$67.6 million in FY2022.
For a complete picture of EDG-7500’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
